Protocol Ledger

NCT04137107 · Phase II/III · ACTIVE NOT RECRUITING

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

Interventional Phase II/III clinical trial protocol NCT04137107 sponsored by Alliance for Clinical Trials in Oncology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-06-17 Enrollment: 220 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04137107
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)220 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04137107
Protocol FieldVerified Registry Value
NCT IdentifierNCT04137107
Consolidated Lead SponsorAlliance for Clinical Trials in Oncology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment220 participants (ACTUAL)
Registered Start Date2020-06-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI